Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), Qian Miao(Fujian Medical University), Bo Zhu(Huaian First People’s Hospital), Zhefeng Liu(Chinese People's Liberation Army), Fan Yang(Peking University People's Hospital), Weineng Feng(First People's Hospital of Foshan), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yi Hu(Union Hospital), Tangfeng Lv(Southeast University), Mingqiu Chen(Fujian Medical University), Zhe Liu(Capital Medical University), Jie Hu(Zhongshan Hospital), Kan Jiang(Fujian Medical University), Yabing Cao(Xi'an Polytechnic University), Shuitu Feng(Xiamen Chang Gung Hospital), Anwen Liu(Nanchang University), Jianchun Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Meijuan Huang, Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Yan Huang(Chinese PLA General Hospital), Chao Li(Qingdao University), Xiaohui Chen(Nagasaki University), Jun Wang(Shenzhen Bao'an District People's Hospital), Min Li(117th Hospital of People's Liberation Army), Zhijie Wang(Hubei University of Medicine), Zhenhua Liu(Hangzhou First People's Hospital), Yutao Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Cheng‐Bo Han, Si‐Yang Maggie Liu(University of Arizona), Yun Fan(Zhejiang Cancer Hospital), Jisheng Li(Shandong Tumor Hospital), Jie Lin(Kunming Medical University), Yuping Lu(Fujian Medical University), Tianqing Chu, Shi Jin(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Jin, Ziming Li(Shanghai Jiao Tong University), Zhigang Liu(Fujian Medical University), Hui Guo(Shandong University of Technology), Da Jiang(Hebei Medical University), Baoshan Cao(Peking University), Xinghao Ai(Shanghai Chest Hospital), Yong Fang(Tongji Hospital), Qian Chu(Tongji Hospital), Zhentian Liu, Shaodong Hong(Sun Yat-sen University), Richeng Jiang(Tianjin Medical University Cancer Institute and Hospital), Zhiyong Ma(Zhengzhou University), Yong He(Army Medical University)
Cited by 5
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
T-cell exhaustion in the tumor microenvironment
|Cell Death and Disease|2015|1.1k
Notch signaling pathway: architecture, disease, and therapeutics
|Signal Transduction and Targeted Therapy|2022|1k
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644
Clinical characteristics of 82 cases of death from COVID-19
|PLoS ONE|2020|594